Human Medicine:

Latent Tuberculosis Infection (LTBI) Testing

SYNLAB specialises in providing end to end services for the diagnosis of Latent Tuberculosis Infection (LTBI) in accordance with UK government guidelines, and is experienced in carrying out a broad range of pathology services in support of clinical trials.

LTBI screening can help prevent the spread of Tuberculosis (TB), with early detection improving treatment outcomes. Screening days and individual test options available.

  • 1 in 4 people worldwide estimated to have latent TB infection, 5-10% of which likely to develop active TB within 5 years if left untreated.*
  • Gamma Release Assays (IGRAs) test supporting the NICE guidelines for TB screening.
  • People with LTBI typically have no symptoms or physical findings suggestive of TB disease.
  • Screening day project set up and management services, including provision of kits and phlebotomist.

SCREENING TEST FOR HIGH RISK POPULATIONS

High risk populations include those with weakened immune systems, in recent contact with TB infection, recent travel to countries / areas with TB outbreaks, live or work in high risk settings such as prisons, healthcare / nursing homes and shelters, as well as educational institutes. In addition:

  • People in hard to reach groups.
  • Anyone aged 5 years and older in an outbreak situation where a large number of contacts need to be tested.
  • New NHS healthcare workers, if they have recently arrived from high incidence countries, or if they have had contact with patients in settings where TB is highly prevalent.
  • Immunocompromised patients with HIV and CD4 counts < 500 cells/mm3.
  • Immunocompromised patients with prolonged steroid use, use of TNF alpha antagonists or drugs used to prevent rejection of transplanted organs.

Contact Us to find out more about SYNLAB’s LTBI screening services.

* Source: World Health Organization

Latest Human Medicine News
SYNLAB launch Faecal Immunochemical Testing (FIT)

23rd July 2019 – SYNLAB have announced the launch of Faecal Immunochemical Testing (FIT), a bowel / colorectal cancer screening test. FIT is a more…

Read More (about 'SYNLAB launch Faecal Immunochemical Testing (FIT)')
Leukaemia patient goes behind the scenes at The Christie Pathology Partnership

As part of National Biomedical Science Day, the Christie Pathology Partnership (CPP), based at The Christie in Manchester, opened its doors and gave a special…

Read More (about 'Leukaemia patient goes behind the scenes at The Christie Pathology Partnership')
Healthcare Science – an insight into working at Pathology First

Matt Jeffery, Operations Manager at Pathology First explains how he achieved his role, how the profession is evolving and what it’s like to lead the…

Read More (about 'Healthcare Science – an insight into working at Pathology First')
Healthcare Science Week – what’s it like being a Biomedical Scientist (BMS) at Europe’s largest cancer centre?

Jamie Wild is a Biomedical Scientist (BMS) at the Christie Pathology Partnership (CPP), one of the UK’s leading reference centres specialising in cancer detection and…

Read More (about 'Healthcare Science Week – what’s it like being a Biomedical Scientist (BMS) at Europe’s largest cancer centre?')